An FDA advisory committee voted on Thursday to add the popular peptide BPC-157 to a drug compounding list.

A FDA advisory committee will review evidence surrounding peptides. Experts are concerned there is a paucity of evidence to back their approval for legal compounding.

Votes go against agency scientists' recommendation to keep them off the compounding list